Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

被引：349

作者：

Tan, Jiahuai ^{[2
]}

Cang, Shundong ^{[3
]}

Ma, Yuehua ^{[1
]}

Petrillo, Richard L. ^{[2
]}

Liu, Delong ^{[1
]}

机构：

[1] New York Med Coll, Div Hematol Oncol, Valhalla, NY 10595 USA

[2] Mt Vernon Hosp, Dept Med, Mt Vernon, NY 10550 USA

[3] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2010年 / 3卷

关键词：

TRANS-RETINOIC ACID; CHRONIC LYMPHOCYTIC-LEUKEMIA; REFRACTORY SOLID TUMORS; ACUTE MYELOID-LEUKEMIA; ACTIVITY IN-VITRO; VALPROIC ACID; PHASE-I; HDAC INHIBITOR; BELINOSTAT PXD101; EPIGENETIC MODIFICATIONS;

D O I：

10.1186/1756-8722-3-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin. Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs. One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies. Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combination with other anti-tumor drugs in CTCL and other malignancies. At least 80 clinical trials are underway, testing more than eleven different HDAC inhibitory agents including both hematological and solid malignancies. This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents.

引用

页数：13

共 146 条

[1] HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination [J].

Adimoolam, Shanthi ;

Sirisawad, Mint ;

Chen, Jun ;

Thiemann, Patti ;

Ford, James M. ;

Buggy, Joseph J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (49) :19482-19487

[2]

[Anonymous], J CLIN ONCOL S

[3] Valproic acid (VPA) in patients with refractory advanced cancer:: a dose escalating phase I clinical trial [J].

Atmaca, A. ;

Al-Batran, S-E ;

Maurer, A. ;

Neumann, A. ;

Heinzel, T. ;

Hentsch, B. ;

Schwarz, S. E. ;

Hovelmann, S. ;

Goettlicher, M. ;

Knuth, A. ;

Jaeger, E. .

BRITISH JOURNAL OF CANCER, 2007, 97 (02) :177-182

[4] Histoine deacetylase inhibitors in cancer therapy: Latest developments, trends and medicinal chemistry perspective [J].

Balakin, Konstantin V. ;

Ivanenkov, Yan A. ;

Kiselyov, Alex S. ;

Tkachenko, Sergey E. .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2007, 7 (05) :576-592

[5] Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors [J].

Bali, P ;

Pranpat, M ;

Bradner, J ;

Balasis, M ;

Fiskus, W ;

Guo, F ;

Rocha, K ;

Kumaraswamy, S ;

Boyapalle, S ;

Atadja, P ;

Seto, E ;

Bhalla, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) :26729-26734

[6] Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain [J].

Bannister, AJ ;

Zegerman, P ;

Partridge, JF ;

Miska, EA ;

Thomas, JO ;

Allshire, RC ;

Kouzarides, T .

NATURE, 2001, 410 (6824) :120-124

[7] Radiosensitization by the histone deacetylase inhibitor PCI-24781 [J].

Banuelos, Carmen A. ;

Banath, Judit P. ;

MacPhail, Susan H. ;

Zhao, Jin ;

Reitsema, Tarren ;

Olive, Peggy L. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6816-6826

[8] Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells [J].

Barbetti, V. ;

Gozzini, A. ;

Rovida, E. ;

Morandi, A. ;

Spinelli, E. ;

Fossati, G. ;

Mascagni, P. ;

Luebbert, M. ;

Dello Sbarba, P. ;

Santini, V. .

ONCOGENE, 2008, 27 (12) :1767-1778

[9]

Beardsley Emma K, 2008, Curr Opin Support Palliat Care, V2, P161, DOI 10.1097/SPC.0b013e32830c48a3

[10] An embarrassment of niches: the many covalent modifications of histones in transcriptional regulation [J].

Berger, SL .

ONCOGENE, 2001, 20 (24) :3007-3013

← 1 2 3 4 5 6 7 8 9 10 →